2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: MXene and MAX Phase Materials · Advanced biosensing and bioanalysis techniques · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The novel coronavirus COVID-19 outbreak: global implications for antimicrobial resistance10.3389/fmicb.2020.01020 ↗
2. An interactive web-based dashboard to track COVID-19 in real time10.1016/S1473-3099(20)30120-1 ↗
3. Knobler · 2005
4. Toward nanotechnology-enabled approaches against the COVID-19 pandemic10.1021/acsnano.0c03697 ↗
5. Nanotechnology-based disinfectants and sensors for SARS-CoV-210.1038/s41565-020-0751-0 ↗
6. How can nanotechnology help to combat COVID-19? Opportunities and urgent need10.1186/s12951-020-00685-4 ↗
7. Tackling COVID-19 pandemic through nanocoatings: confront and exactitude
8. De Maio · Graphene nanoplatelet and graphene oxide functionalization of face mask materials inhibits infectivity of trapped SARS-CoV-2 · 2020
9. Phage capsid nanoparticles as multivalent inhibitors of viral infections10.1016/j.scib.2020.09.019 ↗
10. COVID-19 acute responses and possible long term consequences: what nanotoxicology can teach us10.1016/j.nantod.2020.100945 ↗
11. Can graphene take part in the fight against COVID-19?10.1016/j.nantod.2020.100883 ↗
12. Nano-targeting lessons from the SARS-CoV-210.1016/j.nantod.2020.101012 ↗
13. Using nano-selenium to combat coronavirus disease 2019 (COVID-19)?10.1016/j.nantod.2020.101037 ↗
14. A materials-science perspective on tackling COVID-1910.1038/s41578-020-00247-y ↗
15. Sensitive, rapid, low-cost, and multiplexed COVID-19 monitoring by the wireless telemedicine platform10.1016/j.matt.2020.11.001 ↗
16. Emerging two-dimensional monoelemental materials (Xenes) for biomedical applications10.1039/C8CS00823J ↗
17. Pnictogens in medicinal chemistry: evolution from erstwhile drugs to emerging layered photonic nanomedicine
18. Insights from nanotechnology in COVID-19 treatment10.1016/j.nantod.2020.101019 ↗
19. COVID-19 vaccine development and a potential nanomaterial path forward10.1038/s41565-020-0737-y ↗
20. COVID-19 vaccine frontrunners and their nanotechnology design10.1021/acsnano.0c07197 ↗
21. Nanomedicine and the COVID-19 vaccines, Nat. Nanotechnol., 15, 2020, 963–963.10.1038/s41565-020-00820-0 ↗
22. Graphene and other 2D materials: a multidisciplinary analysis to uncover the hidden potential as cancer theranostics10.7150/thno.40068 ↗
23. Graphene, other carbon nanomaterials and the immune system: toward nanoimmunity-by-design10.1088/2515-7639/ab9317 ↗
24. Diverse applications of nanomedicine10.1021/acsnano.6b06040 ↗
25. Two-dimensional materials for antimicrobial applications: graphene materials and beyond10.1002/asia.201800851 ↗
26. Biocompatibility and biodegradability of 2D materials: graphene and beyond10.1039/C9CC01205B ↗
27. Biomedical uses for 2D materials beyond graphene: current advances and challenges ahead10.1002/adma.201506306 ↗
28. Photocatalytically active graphitic carbon nitride as an effective and safe 2D material for in vitro and in vivo photodynamic therapy
29. Photodynamic therapy based on graphene and MXene in cancer theranostics10.3389/fbioe.2019.00295 ↗
30. Two-dimensional nanocrystals produced by exfoliation of Ti3AlC210.1002/adma.201102306 ↗
31. The rise of MXenes10.1021/acsnano.9b06394 ↗
32. Two-dimensional, ordered, double transition metals carbides (MXenes)10.1021/acsnano.5b03591 ↗
33. Synthesis of Mo4VAlC4 MAX phase and two-dimensional Mo4VC4 MXene with five atomic layers of transition metals10.1021/acsnano.9b07708 ↗
34. Tailoring electronic and optical properties of mxenes through forming solid solutions10.1021/jacs.0c07395 ↗
35. Guidelines for synthesis and processing of two-dimensional titanium carbide (Ti3C2Tx MXene)10.1021/acs.chemmater.7b02847 ↗
36. MXenes: an introduction of their synthesis, select properties, and applications10.1016/j.trechm.2019.04.006 ↗
37. The broad chromatic range of two-dimensional transition metal carbides10.1002/adom.202001563 ↗
38. Recent progress in two-dimensional antimicrobial nanomaterials10.1002/chem.201801983 ↗
39. Two-dimensional transition metal carbides and nitrides (MXenes) for biomedical applications10.1039/C7CS00838D ↗
40. Post-graphene 2D materials-based antimicrobial agents: Focus on fabrication strategies and biosafety assessments10.1007/s10853-020-04507-8 ↗
41. Antibacterial applications of graphene-based nanomaterials: recent achievements and challenges10.1016/j.addr.2016.04.009 ↗
42. Graphene materials in antimicrobial nanomedicine: current status and future perspectives
43. The antibacterial applications of graphene and its derivatives10.1002/smll.201601841 ↗
44. Two-dimensional tantalum carbide (MXenes) composite nanosheets for multiple imaging-guided photothermal tumor ablation10.1021/acsnano.7b07241 ↗
45. Ecotoxicological assessment of Ti3C2Tx (MXene) using a zebrafish embryo model10.1039/C7EN01239J ↗
46. Highly catalytic niobium carbide (MXene) promotes hematopoietic recovery after radiation by free radical scavenging10.1021/acsnano.8b09327 ↗
47. Ultrathin molybdenum carbide MXene with fast biodegradability for highly efficient theory-oriented photonic tumor hyperthermia10.1002/adfm.201901942 ↗
48. Antibacterial activity of Ti3C2Tx MXene10.1021/acsnano.6b00181 ↗
49. Efficient antibacterial membrane based on two-dimensional Ti3C2Tx (MXene) nanosheets10.1038/s41598-017-01714-3 ↗
50. Ultrahigh-flux and fouling-resistant membranes based on layered silver/mxene (Ti3C2Tx) nanosheets10.1039/C7TA10888E ↗
51. The atomic structure of Ti2C and Ti3C2 MXenes is responsible for their antibacterial activity toward E. coli bacteria10.1007/s11665-018-3223-z ↗
52. Biological and environmental interactions of emerging two-dimensional nanomaterials10.1039/C5CS00914F ↗
53. Functionalized nanographene sheets with high antiviral activity through synergistic electrostatic and hydrophobic interactions10.1039/C9NR05273A ↗
54. Antimicrobial properties of 2D MnO2 and MoS2 nanomaterials vertically aligned on graphene materials and Ti3C2 MXene10.1021/acs.langmuir.8b00262 ↗
55. Herpes simplex virus type-1 attachment inhibition by functionalized graphene oxide10.1021/am405040z ↗
56. Antiviral activity of graphene oxide: How sharp edged structure and charge matter10.1021/acsami.5b06876 ↗
57. Graphene-based “hot plate” for the capture and destruction of the herpes simplex virus type 110.1021/acs.bioconjchem.7b00030 ↗
58. Immunological impact of graphene oxide sheets in the abdominal cavity is governed by surface reactivity10.1007/s00204-018-2303-z ↗
59. Graphene and the immune system: challenges and potentiality10.1016/j.addr.2016.05.014 ↗
60. Safety assessment of graphene-based materials: focus on human health and the environment10.1021/acsnano.8b04758 ↗
61. Inside nano: a systems biology framework to contextualize the mechanism-of-action of engineered nanomaterials10.1038/s41598-018-37411-y ↗
62. Characterization of mxenes at every step, from their precursors to single flakes and assembled films
63. X-ray photoelectron spectroscopy of select multi-layered transition metal carbides (MXenes)10.1016/j.apsusc.2015.11.089 ↗
64. Scalable synthesis of Ti3C2Tx MXene10.1002/adem.201901241 ↗
65. On the origin and continuing evolution of SARS-CoV-210.1093/nsr/nwaa036 ↗
66. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide10.1038/s41598-020-70827-z ↗
67. Atomistic simulation reveals structural mechanisms underlying D614G spike glycoprotein-enhanced fitness in SARS-CoV-210.1002/jcc.26383 ↗
68. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity10.1016/j.cell.2020.07.012 ↗
69. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus10.1016/j.cell.2020.06.043 ↗
70. A comprehensive mapping of the druggable cavities within the SARS-CoV-2 therapeutically relevant proteins by combining pocket and docking searches as implemented in pockets 2.010.3390/ijms21145152 ↗
71. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing10.1038/s41586-020-2286-9 ↗
72. COVID-19 transmission through host cell directed network of GPCR10.1002/ddr.21674 ↗
73. Subcellular hot spots of GPCR signaling promote vascular inflammation10.1016/j.coemr.2020.07.011 ↗
74. Mitochondrial-targeted ubiquinone: a potential treatment for COVID-1910.1016/j.mehy.2020.110161 ↗
75. The role of genetic sex and mitochondria in response to COVID-19 infection10.1159/000508560 ↗
76. Letter to the editor: COVID-19, mitochondria, and interferon10.1089/jir.2020.0112 ↗
77. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis10.1152/ajpcell.00224.2020 ↗
78. RNA-GPS predicts SARS-CoV-2 RNA localization to host mitochondria and nucleolus10.1016/j.cels.2020.06.008 ↗
79. Single-cell mass cytometry and transcriptome profiling reveal the impact of graphene on human immune cells10.1038/s41467-017-01015-3 ↗
80. Visne enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia10.1038/nbt.2594 ↗
81. A platinum-based covalent viability reagent for single-cell mass cytometry10.1002/cyto.a.22067 ↗
82. Across speciality collaboration, COVID-19: consider cytokine storm syndromes and immunosuppression10.1016/S0140-6736(20)30628-0 ↗
83. Clinical and immunological features of severe and moderate coronavirus disease 201910.1172/JCI137244 ↗
84. Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research10.1080/17425247.2018.1420053 ↗
85. Hierarchical porous carbide-derived carbons for the removal of cytokines from blood plasma10.1002/adhm.201200044 ↗
86. CD8+HLA-DR+ T lymphocytes are increased in common variable immunodeficiency patients with impaired memory b-cell differentiation10.1016/j.clim.2005.11.011 ↗
87. Perforin and granzymes: function, dysfunction and human pathology10.1038/nri3839 ↗
88. Granzyme K synergistically potentiates LPS-induced cytokine responses in human monocytes10.1073/pnas.1317347111 ↗
89. Controlling cytokine storm is vital in COVID-1910.3389/fimmu.2020.570993 ↗
90. Into the eye of the cytokine storm10.1128/MMBR.05015-11 ↗
91. Melanoma NOS1 expression promotes dysfunctional IFN signaling10.1172/JCI69611 ↗
92. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-210.1038/bjc.2013.557 ↗
93. CXCL10 could drive longer duration of mechanical ventilation during COVID-19 ards10.1186/s13054-020-03328-0 ↗
94. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system10.1016/j.cytogfr.2020.05.003 ↗
95. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients10.1080/22221751.2020.1747363 ↗
96. Y. Yang, C. Shen, J. Li, J. Yuan, M. Yang, F. Wang, G. Li, Y. Li, L. Xing, L. Peng, J. Wei, M. Cao, H. Zheng, W. Wu, R. Zou, D. Li, Z. Xu, H. Wang, M. Zhang, Z. Zhang, L. Liu, Y. Liu, Exuberant Elevation of IP-10, MCP-3 and IL-1 Raduring SARS-CoV-2 Infection is Associated with Disease Severity and Fataloutcome, medRxiv, 2020, 2020.2003.2002.20029975.10.1101/2020.03.02.20029975 ↗
97. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-1910.1016/j.jaci.2020.04.027 ↗
98. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease10.1016/j.cytogfr.2020.06.001 ↗
99. Post-graphene 2D materials-based antimicrobial agents: focus on fabrication strategies and biosafety assessments10.1007/s10853-020-04507-8 ↗
100. Nanomaterials designed for antiviral drug delivery transport across biological barriers10.3390/pharmaceutics12020171 ↗